Ovarian Cancer After Breast Cancer in Women with BRCA Variants
Editor’s Choice: Ovarian cancer after breast cancer in women with a BRCA1 or BRCA2 pathogenic variant
--------
28:31
--------
28:31
Understanding the Implications of the Platinum-Free Interval in Endometrial Cancer
Editor’s Choice: Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study
Editorial: Implications of the Platinum-Free Interval in Endometrial Cancer: A Legacy Worth Leaving Behind?
Hosted by:Warner Huh, MD, Deputy Editor of Gynecologic OncologyFeaturing: Paulina Haight, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center, James Hospital and Solove Research Institute, Columbus, OH, United States of AmericaRamez N. Eskander, MD, UC San Diego School of Medicine, Moores Cancer Center at UC San Diego Health, San Diego, CA
--------
16:12
--------
16:12
Editor’s Choice: Lunchbox Trial
Editor’s Choice Paper: Lunchbox trial: A randomized phase III trial of cisplatin and irradiation followed by carboplatin and paclitaxel versus sandwich therapy of carboplatin and paclitaxel followed by irradiation then carboplatin and paclitaxel for advanced endometrial carcinoma Editorial:What's in your “lunchbox”? Sandwich versus sequential chemotherapy and irradiation for advanced endometrial cancerHosted by:Ursula Matulonis, MD, Associate Editor of Gynecologic OncologyFeaturing:Joyce Barlin, MD, Women’s Cancer Care Associates & Albany Medical CollegeGretchen Glaser, MD, Mayo Clinic John Weroha, MD, Mayo Clinic
--------
10:18
--------
10:18
May 2023 Editor's Choice: Prioritizing and achieving diversity in clinical trial enrollment
Editor’s Choice Papers: What's in it for me?: A value assessment of gynecologic cancer clinical trials for Black women Editorial: Achieving diversity in clinical trial enrollment by reducing burden and increasing value: A patient-centered approachHosted by:Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology Featuring: Ann Oluloro, MD, MPH, University of WashingtonEloise Chapman-Davis, MD, Weill Cornell Medicine
--------
--------
Making a difference: Molecules, mechanisms and more
Editor’s Choice: A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer
Colombia